Prior to joining the EMA, Dr Purves was manager of the
biotechnology and biological unit, for 21 years, at the UK Medicines Control
Agency, now the Medicines and Healthcare products Regulatory Agency. At the UK
agency, he was involved in the drafting of some legislation, and of a number of
supportive European Union guidelines, dealing with the manufacture and control
of recombinant-DNA products and products derived from human blood and plasma.
Dr Purves also oversaw efforts to minimise the risk of the transmission of
spongiform encephalopathies to humans through medicinal products.
Dr Christian van den Bos serves as Executive Program
Manager at Lonza and drives Lonza’s development efforts for advanced stem cell
products.
Dr van den Bos has over 15 years of experience in cell therapy
work and has managed cell therapy projects ranging from early R&D to
production, regulatory and clinical trials.
Prior to joining Lonza he served as Sr. VP, EU
Affairs for Cytograft, USA, as Head of Development and Operations for Symetis,
Switzerland &Germany, as VP of R&D for Viacell Europe, Germany, as
Director, Biologics, for Spectra Stable Isotopes/Martek Biosciences, USA and as
Sr. Scientist for Osiris Therapeutics, Baltimore, Maryland.
Dr Gert De Beckker is Head Regulatory Affairs at TiGenix NV, a late stage biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. In the past 2.5 years he was responsible for the centralized marketing authorization application of ChondroCelect a cell based therapy. This lead product of Tigenix was granted marketing authorization on October 5th 2009.
Dr Gert De Beckker is Head Regulatory Affairs at TiGenix NV, a late stage biomedical company that focuses on innovative local treatments for damaged and osteoarthritic joints. In the past 2.5 years he was responsible for the centralized marketing authorization application of ChondroCelect a cell based therapy. This lead product of Tigenix was granted marketing authorization on October 5th 2009.
